11 assets in Obstructive Sleep Apnea Syndrome

Therapeutic assets addressing Obstructive Sleep Apnea Syndrome, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Melatonin Obstructive Sleep Apnea Syndrome	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran	P4	BB (65)
Eloralintide Obstructive Sleep Apnea Syndrome	Eli Lilly and Company	P3	B (60)
Mazdutide Obstructive Sleep Apnea Syndrome	Innovent Biologics (Suzhou) Co. Ltd.	P3	B (60)
nnc0487-0111 Obstructive Sleep Apnea Syndrome	Novo Nordisk A/S	P3	B (60)
Orforglipron Obstructive Sleep Apnea Syndrome	Eli Lilly and Company	P3	B (60)
xw003 Obstructive Sleep Apnea Syndrome	Hangzhou Sciwind Biosciences Co., Ltd.	P3	B (60)
AIR Obstructive Sleep Apnea Syndrome	University of California, San Diego	P1	CC (47)
Oxygen Obstructive Sleep Apnea Syndrome	University of California, San Diego	P1	CC (47)
gzr18 Obstructive Sleep Apnea Syndrome	Gan & Lee Pharmaceuticals.	P3	NR ()
hrs9531 Obstructive Sleep Apnea Syndrome	Fujian Shengdi Pharmaceutical Co., Ltd.	P3	NR ()